Physician Photo

Herminia Diana (Diana) Rosas, MD

Director, Center for Neuro-imaging of Aging and Neurodegenerative Disease

  • Phone: 617-726-1728
Department of Neurology
Clinical Interests
Huntington's disease
Alzheimer's disease
Boston: Massachusetts General Hospital
Medical Education
MD, University of Chicago Pritzker School of Medicine
Residency, Massachusetts General Hospital
Board Certifications
Neurology, American Board of Psychiatry and Neurology
Patient Gateway
Yes, learn more
Foreign Languages
Patient Age Group
Accepting New Patients
Accepting New Patients

ResearchDr. Rosas and her team have focused primarily on the development of biomarkers for use in the study of neurodegenerative diseases, to better characterize progression, to better understand genotype/phenotype correlations, and to apply novel neuroimaging approaches in clinical trials with the overall aim of making them more efficient. We have begun to develop models that may explain clinically heterogeneous phenotypes and variability in disease progression. The current models for both disease prediction and prediction of disease progression are insensitive and inaccurate. We are planning to expand our efforts to include multi-modal and multi-spectral imaging approaches that promise both more precise measurements and made provide novel and important information on the neural underpinnings of HD and their clinical consequences.


View my most recent publications at PubMed

1.Rosas HD, Zaleta AK, Lee SY, Pappu V, Salat DH, Hersch SM (2008) Complexity and heterogeneity: The role of the cortex in the clinical expression of HDN Brain Apr 131: 1057-68.3.Rosas HD, LeeSY, BenderAC, ZaletaAK, VangelM, YuP, FischlB, PappuV,OnoratoC, ChaJH,Salat DH,Hersch S. Altered white matter microstructure inthe corpus callosum in Huntingto?s disease: implications for cortical*disconnection. (2010)NeuroImage.49; 2995-3. 4.SalatDH, ChenJJ, vanderKouwe AJ, GreveDN, FischlB, RosasHD.Hippocampal degeneration is associated with temporal and limbic gray/whitematter tissue contrast in Alzheimers disease.(2011)NeuroImage; 54,1795-802. 5.Rosas HD, ReuterM, DorosG, LeeSY, TriggsTT, MalarickK,Fischl B,Salat DH,HerschSM. A Tale of Two Factors: What better determines rate of progressionin HD, age or CAG repeat?(2010) Movement Disorders.

First Huntington disease prevention trial shows treatment safety, suggests slowing of presymptomatic progression

The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants. In addition, neuroimaging provided evidence that creatine might slow the progression of presymptomatic disease.

Neurology Associates
15 Parkman Street
Boston, MA 02114-3117

Phone: 617-726-1728
Phone 2: 617-726-5532
Fax: 617-726-4101